Canada Nuclear Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Canada Nuclear Imaging Market Trends and Insights

Growing Prevalence of Cancer & CVD

Canada registered 247,100 new cancer cases and 88,100 cancer deaths in 2024, while 2.4 million adults live with cardiovascular disease, a burden that is reshaping diagnostic pathways.^{[1]Canadian Cancer Society, “Canadian Cancer Statistics 2024,” Canadian Cancer Society, cancer.ca} FDG PET/CT stays central for non-small-cell lung cancer staging, whereas gallium-68 PSMA PET is now displacing conventional imaging for intermediate- and high-risk prostate cancer after Health Canada cleared Pluvicto in 2022.^{[2] Health Canada, “Notice of Compliance: Pluvicto,” Government of Canada, canada.ca} Rubidium-82 cardiac PET attracts cardiology departments because it delivers 75% less radiation than technetium-99m SPECT. Cancer Care Ontario plans six additional PET scanners by 2028, reinforcing capacity in underserved regions.The Canada nuclear imaging market therefore enjoys a 1.8-percentage-point CAGR lift tied directly to disease-burden growth.

Rising Adoption of Hybrid PET/CT & SPECT/CT

The 2022–2023 Canadian Medical Imaging Inventory listed 60 PET/CT and 331 SPECT/CT units compared with 210 standalone SPECT cameras that now average 13.2 years of service.^{[3]Canadian Agency for Drugs and Technologies in Health, “Canadian Medical Imaging Inventory 2021-2022,” CADTH, cadth.ca} Integrated scanners shorten time-to-diagnosis and reduce interpretive uncertainty because anatomical and functional data are co-registered in one session. New digital platforms such as GE HealthCare’s Omni Legend and Siemens Healthineers’ Biograph Vision Quadra increase photon sensitivity two- to three-fold, which translates into 50% lower dose or 40% faster acquisitions. Provincial health authorities in Nova Scotia and British Columbia funded digital SPECT/CT installations in 2024, signaling growing willingness to back premium technology. Rising hybrid adoption contributes an additional 1.5-percentage-point lift to the Canada nuclear imaging market CAGR.

Government Investments in Radiopharmaceutical Capacity

After the National Research Universal reactor closed in 2018, Canada pivoted towards cyclotron-based isotope production. TRIUMF obtained CAD 35 million (USD 26 million) in 2023 to develop a national isotope ecosystem that includes gallium-68 and actinium-225. British Columbia’s CAD 32 million cyclotron and Alberta’s Calgary Radiopharmaceutical Centre, under construction through 2027, decentralize supply and shorten delivery times for short-lived tracers. BWXT Medical’s Target Delivery System at Darlington gained a license in 2023 and now produces molybdenum-99, yttrium-90, and indium-111. These projects raise domestic self-sufficiency and add 1.2 percentage points to the market’s forecast CAGR.

Digital Detector Innovations Lowering Dose

Cadmium zinc telluride detectors in SPECT and silicon photomultiplier arrays in PET convert photons to electrical signals with higher efficiency, doubling photon sensitivity and sharpening energy resolution. The Queen Elizabeth II Health Sciences Centre documented a 40% technetium-99m dose reduction for myocardial perfusion studies after installing a GE StarGuide SPECT/CT in 2024. Nanaimo Regional General Hospital achieved similar results, halving bone-scan acquisition time while expanding daily capacity. Dose optimization aligns with Health Canada radiation-safety guidelines and partially offsets workforce shortages, delivering a 0.9-percentage-point CAGR boost.

Radio-Isotope Supply Risks Post-NRU Closure

With domestic molybdenum-99 production absent until BWXT Medical’s ramp-up hits full stride, many hospitals still depend on South African and European reactors for technetium-99m generators. Transport disruptions can delay deliveries of isotopes whose half-life is just six hours, forcing postponement of non-urgent scans. TRIUMF’s direct cyclotron production, though approved, satisfies only a fraction of national demand. British Columbia and Alberta projects will narrow the gap by 2027, but Atlantic provinces and northern territories will remain vulnerable to weather-related shipping delays. The result is a -1.1 percentage-point drag on the Canada nuclear imaging market CAGR.

High Capex & Opex of Hybrid Scanners

PET/CT units cost USD 1.8 million–3.5 million, SPECT/CT units require USD 1.5 million–2.5 million, and annual service contracts can top USD 0.5 million. Utilization below about 1,200 scans per year risks negative returns, a barrier for smaller hospitals. Forty-one percent of PET/CT systems already exceed ten years of age, signaling deferred replacement cycles. Leasing mitigates upfront cost yet raises lifetime expense by 20%–30%. Consequently, capital constraints subtract 0.8 percentage points from the Canada nuclear imaging market’s trend growth.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Modality: Hybrid Platforms Sustain Leadership While PET/MR Accelerates

Hybrid PET/CT generated 39.35% of modality revenue in 2025, underlining its entrenched role in oncology staging and therapy response. Stand-alone SPECT cameras are declining as hospitals pivot to hybrid SPECT/CT systems that offer both functional and anatomical data without requiring patient relocation. The Canada nuclear imaging market size for hybrid PET/CT modalities is projected to climb at the overall 6.28% CAGR, whereas hybrid PET/MR leads with a 10.24% CAGR due to superior soft-tissue contrast essential for neuro-oncology and inflammatory bowel disease. Equipment makers have responded: GE HealthCare’s 32 cm-axial Omni Legend shortens total-body scan time to 12 minutes, and Siemens Healthineers’ 106 cm-axial Biograph Vision Quadra enables simultaneous multi-organ pharmacokinetics for theranostic dosimetry. Digital cadmium zinc telluride detectors in next-generation SPECT/CT deliver twice the photon sensitivity of legacy photomultiplier tubes, permitting 50% dose cuts that help labs meet dose-optimization mandates. Hospitals in Halifax and Nanaimo adopted such systems in 2024, evidencing readiness to pay premium prices when dose savings and higher throughput combine. As old SPECT fleets age out—the average system is 13.2 years—the Canada nuclear imaging market share held by hybrid scanners will keep widening.

By Component: Equipment Still Dominates Yet Software Gains Momentum

Equipment captured 63.63% of component revenue in 2025 because several provinces budgeted for hybrid-scanner replacements, but software subscriptions are rising at 9.57% annually as AI-driven image-reconstruction and lesion-quantification tools become standard. The Canada nuclear imaging market size tied to software is therefore growing faster than hardware even though suppliers often bundle first-year licenses with scanner deals. AI-assisted quantification from Siemens’ AI-Rad Companion or GE HealthCare’s Edison platform cuts radiologist reading time 30%–40%, a critical benefit when staffing is tight. Vendors now price upgrades on a per-study or annual-license basis, creating resilient recurring revenue. Consumables such as radiopharmaceutical doses and quality-control phantoms ride on procedure volumes, which expand at the overall 6.28% CAGR. BWXT Medical’s domestic yttrium-90 and indium-111 production will further anchor recurring consumable revenue as isotope self-sufficiency improves.

By Radio-Isotope: Fluorine-18 Retains Primacy, Gallium-68 Surges

Fluorine-18 contributed 37.94% of isotope revenue in 2025 because FDG PET/CT occupies the oncology mainstream and the 110-minute half-life supports regional distribution. Technetium-99m remains indispensable for bone, cardiac, and renal scanning, yet supply risks continue until domestic molybdenum-99 output stabilizes. Gallium-68 is the fastest-growing isotope at a 10.33% CAGR and underpins PSMA and DOTATATE imaging. Health Canada’s approval of lutetium-177 PSMA-617 in 2022 cemented the theranostic pairing that drives diagnostic gallium-68 use. Provincial cyclotron projects will allow on-site gallium-68 generator production, improving access beyond Ontario. Rubidium-82 cardiac PET gains favor because it delivers 75% lower radiation than technetium-99m SPECT while avoiding cyclotron dependence. Investigational isotopes such as copper-64 and zirconium-89 are now in Phase II academic trials, setting the stage for diversified isotope portfolios after 2030.

By Application: Oncology Commands, Neurology Accelerates

Oncology absorbed 52.68% of application revenue in 2025 thanks to FDG PET/CT and accelerating PSMA PET utilization. Neurology is forecast to grow at 8.29% CAGR as amyloid and tau PET tracers gain reimbursement, enabling earlier Alzheimer’s differentiation. Cardiology sits second in share; the shift from SPECT to PET proceeds as rubidium-82 generators lower dose and improve accuracy. Endocrinology remains a smaller yet steady niche, rooted in iodine-based thyroid imaging and therapy. Infection and inflammation studies continue contracting as CT and MRI alternatives mature. Large provincial cancer-centers in British Columbia and Ontario have already embedded PSMA theranostics into routine pathways, underscoring oncology’s catalytic role for the Canada nuclear imaging market.

By End User: Hospitals Hold Lead, Academic Institutes Outpace Growth

Hospitals generated 61.53% of end-user revenue in 2025, reflecting single-payer referral patterns. Diagnostic imaging centers offer shorter waits but still face volume ceilings under provincial reimbursement caps. Academic and research institutes grow fastest at 8.12% CAGR because they secure federal grants and industry partnerships for total-body PET, theranostics, and novel radiopharmaceutical trials. The Canada nuclear imaging market share tilted toward hospitals will gradually narrow as academic centers commercialize innovations that downstream hospitals later adopt. Academic hubs also house new cyclotron facilities that distribute isotopes to regional hospitals, reinforcing their pivotal supply-chain role.

Geography Analysis

Ontario, Quebec, and British Columbia account for nearly 70% of Canada nuclear imaging market capacity because they host large population centers and academic medical networks. Ontario leads on absolute procedure volume, with Princess Margaret Cancer Centre and the Ottawa Hospital anchoring theranostic adoption. Quebec’s CHUM and McGill University Health Centre leverage in-house cyclotrons to support high tracer diversity. British Columbia’s USD 23.7 million University of British Columbia cyclotron, operational since 2026, positions the province as the western isotope hub, cutting delivery times for isotopes whose half-life is less than two hours. Alberta’s Calgary Radiopharmaceutical Centre, slated for completion in 2027, will serve Prairie provinces and trim dependency on Ontario. Atlantic provinces lean on Halifax’s Queen Elizabeth II Health Sciences Centre, where a 2024 digital SPECT/CT upgrade improved throughput and reduced technetium-99m dose, yet patients in rural communities still drive hundreds of kilometers for scans. Northern territories remain dependent on medical evacuations to southern centers because population density cannot justify on-site facilities.

Reimbursement policies shape regional growth. Ontario’s six-scanner expansion aimed for 2028 prioritizes northern and eastern communities, whereas British Columbia funnels nuclear-medicine funding through BC Cancer’s centralized network. Alberta maintains a mixed public-private model, allowing independent imaging centers to contract services, but logistics complexity increases for isotope supply. Technologist shortages further widen regional disparities: vacancy rates climb above 10% in Atlantic Canada, leading to longer appointment backlogs despite hardware upgrades. Decentralized cyclotron investment will alleviate some supply pressure by 2031, yet Ontario’s mature academic ecosystem retains first-mover advantage, maintaining the province’s status as the innovation hub of the Canada nuclear imaging market.

Regulatory Landscape

Nuclear imaging in Canada operates under dual oversight. Health Canada regulates imaging systems and related software as medical devices under the Food and Drugs Act and Medical Devices Regulations. The Canadian Nuclear Safety Commission (CNSC) regulates nuclear substances and prescribed equipment used in isotope production and imaging under the Nuclear Safety and Control Act. Where technologies intersect both domains, Health Canada medical device licensing and CNSC requirements can apply in parallel, which can affect procurement timelines and the sequencing of new platform rollouts.

Coordination mechanisms are designed to reduce duplication across agencies, including a formal Memorandum of Understanding between Health Canada and the CNSC to align oversight for radioisotope-related technologies. On the supply side, licensed nuclear-substance processing capacity is a compliance anchor for radiopharmaceutical continuity. CNSC licensing of facilities such as BWXT Medical Ltd. (licensed through October 31, 2031) supports domestic production and distribution activities that, in turn, shape hospital scan scheduling and tracer availability.

Value Chain Analysis

The Canada nuclear imaging value chain begins with isotope and radiopharmaceutical inputs (target materials, generator components, cold kits, and QC materials), then moves into isotope production and radiopharmaceutical manufacturing across reactor-linked and cyclotron-linked pathways. Major domestic nodes include BWXT Medical, TRIUMF, Canadian Nuclear Laboratories (CNL), Bruce Power, and McMaster University. Downstream distribution is supported by radiopharmacy networks such as Jubilant Radiopharma. Many tracers have short half-lives, so logistics and last-mile delivery remain binding constraints.

Imaging hardware and software then move through OEM manufacturing and Canadian commercialization channels led by companies such as GE HealthCare and Siemens Healthineers. This is followed by installation, acceptance testing, service contracts, and application training delivered with hospital biomedical teams and vendor field organizations. Clinical delivery takes place primarily in hospitals and academic centers, which also function as translation hubs for new protocols and trials. For example, sites such as Lawson Health Research Institute and the QEII Health Sciences Centre act as early adopters for premium hybrid systems, which helps validate workflows that later diffuse to regional hospitals under provincial purchasing and reimbursement frameworks.

Market Opportunities and Future Outlook

Radiopharmaceutical supply resilience is a defined whitespace, especially outside major metro corridors where short-lived tracers and transport variability can tighten scheduling. Government-backed ecosystem building provides a concrete pathway for additional capacity and commercialization, including the Canadian Medical Isotope Ecosystem consortium launched with CAD 35 million in 2023 to strengthen production and distribution across isotopes and radiopharmaceuticals. Facility-led initiatives spanning TRIUMF, BWXT Medical, Bruce Power, and McMaster University also broaden the domestic base for diagnostic and theranostic isotopes.

On the clinical side, opportunities cluster around hybrid imaging and theranostics enablement, where hospitals and academic institutes are investing in platforms and partnerships to expand protocol breadth and throughput. Examples include the Theranostics Center of Excellence collaboration involving St. Josephs Health Care London and Lawson Health Research Institute with GE HealthCare, and CNL working with Jubilant Radiopharma under the Canadian Nuclear Research Initiative-Health program to develop novel alpha radiopharmaceuticals. Demand-side momentum is visible through provincial adoption of advanced hybrid systems. The QEII Health Sciences Centre deployment of StarGuide SPECT/CT in Nova Scotia supports workflow modernization and creates room for software-led productivity layers (AI reconstruction and quantification) that can integrate into existing scanner fleets while addressing technologist and radiologist capacity constraints.